Debashis Ghosh
Concepts (840)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 56 | 2025 | 1771 | 4.970 |
Why?
| | Data Interpretation, Statistical | 28 | 2020 | 377 | 4.480 |
Why?
| | Models, Statistical | 44 | 2024 | 671 | 4.460 |
Why?
| | Leishmaniasis, Visceral | 16 | 2024 | 22 | 4.340 |
Why?
| | Algorithms | 41 | 2025 | 1768 | 4.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 38 | 2016 | 761 | 3.330 |
Why?
| | Computational Biology | 21 | 2025 | 664 | 2.690 |
Why?
| | Computer Simulation | 36 | 2024 | 1015 | 2.590 |
Why?
| | Machine Learning | 10 | 2024 | 556 | 2.550 |
Why?
| | Psychodidae | 7 | 2023 | 8 | 2.210 |
Why?
| | Biomarkers, Tumor | 25 | 2022 | 1258 | 2.180 |
Why?
| | Metabolomics | 9 | 2022 | 704 | 2.140 |
Why?
| | Biometry | 13 | 2011 | 70 | 2.080 |
Why?
| | Software | 16 | 2025 | 678 | 2.060 |
Why?
| | Prostatic Neoplasms | 28 | 2024 | 1049 | 1.820 |
Why?
| | Retinol-Binding Proteins | 5 | 2016 | 17 | 1.740 |
Why?
| | Eye Proteins | 6 | 2016 | 93 | 1.680 |
Why?
| | Neoplasms | 25 | 2024 | 2747 | 1.650 |
Why?
| | Phlebotomus | 5 | 2023 | 5 | 1.440 |
Why?
| | Regression Analysis | 13 | 2021 | 1023 | 1.430 |
Why?
| | Leishmaniasis, Cutaneous | 4 | 2024 | 14 | 1.420 |
Why?
| | Genomics | 12 | 2024 | 815 | 1.320 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 434 | 1.300 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 1048 | 1.290 |
Why?
| | Models, Biological | 14 | 2021 | 1828 | 1.260 |
Why?
| | Proportional Hazards Models | 11 | 2023 | 1268 | 1.240 |
Why?
| | Gene Expression Regulation, Neoplastic | 24 | 2021 | 1435 | 1.230 |
Why?
| | Humans | 198 | 2025 | 141754 | 1.210 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 434 | 1.120 |
Why?
| | Biomarkers | 14 | 2021 | 4190 | 1.120 |
Why?
| | Causality | 4 | 2022 | 131 | 1.110 |
Why?
| | Databases, Factual | 12 | 2024 | 1448 | 1.100 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 327 | 1.090 |
Why?
| | Insecticides | 4 | 2023 | 42 | 1.060 |
Why?
| | Biostatistics | 3 | 2014 | 18 | 1.050 |
Why?
| | Insect Control | 4 | 2023 | 18 | 1.050 |
Why?
| | Insect Vectors | 4 | 2023 | 39 | 1.040 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2024 | 774 | 1.040 |
Why?
| | Aromatase | 2 | 2019 | 32 | 0.990 |
Why?
| | Bangladesh | 13 | 2024 | 56 | 0.980 |
Why?
| | Survival Analysis | 12 | 2024 | 1320 | 0.980 |
Why?
| | Endemic Diseases | 2 | 2024 | 36 | 0.980 |
Why?
| | Natural Gas | 1 | 2025 | 25 | 0.910 |
Why?
| | Oil and Gas Fields | 1 | 2025 | 32 | 0.900 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 185 | 0.900 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 289 | 0.890 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 703 | 0.870 |
Why?
| | Microscopy | 3 | 2023 | 156 | 0.860 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2567 | 0.850 |
Why?
| | Magnetoencephalography | 2 | 2021 | 157 | 0.840 |
Why?
| | Leishmania donovani | 5 | 2022 | 12 | 0.840 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 246 | 0.830 |
Why?
| | Histological Techniques | 1 | 2023 | 40 | 0.810 |
Why?
| | Environmental Exposure | 3 | 2025 | 585 | 0.790 |
Why?
| | Genetic Association Studies | 5 | 2019 | 375 | 0.780 |
Why?
| | Models, Genetic | 11 | 2019 | 592 | 0.780 |
Why?
| | Zebrafish Proteins | 2 | 2016 | 292 | 0.770 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1498 | 0.770 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 450 | 0.770 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 338 | 0.740 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 412 | 0.730 |
Why?
| | Pyrethrins | 1 | 2021 | 8 | 0.730 |
Why?
| | Connectome | 2 | 2021 | 93 | 0.720 |
Why?
| | Mass Spectrometry | 6 | 2022 | 740 | 0.710 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 43 | 0.700 |
Why?
| | Brain Mapping | 2 | 2021 | 532 | 0.690 |
Why?
| | Brain | 4 | 2024 | 2868 | 0.680 |
Why?
| | Housing | 2 | 2021 | 146 | 0.670 |
Why?
| | Endpoint Determination | 2 | 2011 | 78 | 0.670 |
Why?
| | Nitriles | 1 | 2021 | 188 | 0.660 |
Why?
| | Cluster Analysis | 12 | 2024 | 521 | 0.660 |
Why?
| | Propensity Score | 4 | 2018 | 332 | 0.650 |
Why?
| | Feasibility Studies | 2 | 2024 | 1027 | 0.640 |
Why?
| | Phenotype | 12 | 2023 | 3177 | 0.640 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 1057 | 0.620 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 157 | 0.620 |
Why?
| | Placenta | 2 | 2019 | 769 | 0.620 |
Why?
| | Risk Assessment | 8 | 2020 | 3508 | 0.620 |
Why?
| | Databases, Genetic | 11 | 2021 | 243 | 0.610 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 119 | 0.610 |
Why?
| | Learning | 1 | 2023 | 439 | 0.600 |
Why?
| | Genetic Variation | 4 | 2019 | 1000 | 0.600 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 177 | 0.590 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 124 | 0.590 |
Why?
| | Metadata | 1 | 2018 | 16 | 0.580 |
Why?
| | Metabolome | 1 | 2021 | 366 | 0.560 |
Why?
| | Protein Conformation | 4 | 2015 | 941 | 0.550 |
Why?
| | Logistic Models | 12 | 2020 | 2092 | 0.550 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 2096 | 0.540 |
Why?
| | Transcriptome | 2 | 2023 | 1014 | 0.540 |
Why?
| | Glioma | 1 | 2022 | 427 | 0.540 |
Why?
| | Reproducibility of Results | 17 | 2021 | 3356 | 0.530 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1634 | 0.530 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 96 | 0.520 |
Why?
| | Male | 74 | 2025 | 70179 | 0.510 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1739 | 0.510 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1127 | 0.510 |
Why?
| | Registries | 2 | 2024 | 2144 | 0.480 |
Why?
| | Markov Chains | 7 | 2017 | 126 | 0.470 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1977 | 0.470 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2016 | 159 | 0.470 |
Why?
| | Linear Models | 7 | 2018 | 858 | 0.460 |
Why?
| | Crystallography, X-Ray | 7 | 2019 | 485 | 0.450 |
Why?
| | Empirical Research | 2 | 2012 | 22 | 0.440 |
Why?
| | Female | 60 | 2025 | 75943 | 0.440 |
Why?
| | Bayes Theorem | 7 | 2022 | 418 | 0.440 |
Why?
| | Protein Folding | 1 | 2016 | 278 | 0.440 |
Why?
| | Case-Control Studies | 10 | 2025 | 3597 | 0.440 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 89 | 0.430 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 645 | 0.430 |
Why?
| | Lupus Nephritis | 2 | 2025 | 67 | 0.420 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 419 | 0.420 |
Why?
| | Nerve Net | 3 | 2024 | 281 | 0.420 |
Why?
| | Statistics as Topic | 3 | 2025 | 302 | 0.410 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 110 | 0.400 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1406 | 0.400 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 168 | 0.390 |
Why?
| | Spectrometry, Fluorescence | 4 | 2016 | 167 | 0.390 |
Why?
| | India | 6 | 2023 | 208 | 0.390 |
Why?
| | Bias | 5 | 2022 | 229 | 0.390 |
Why?
| | Disease Progression | 15 | 2021 | 2800 | 0.380 |
Why?
| | Treatment Outcome | 9 | 2023 | 11181 | 0.380 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 52 | 0.380 |
Why?
| | Oncogenes | 1 | 2013 | 118 | 0.370 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 188 | 0.360 |
Why?
| | Herpes Zoster Vaccine | 2 | 2025 | 160 | 0.360 |
Why?
| | Animals | 33 | 2025 | 37749 | 0.360 |
Why?
| | Genome | 5 | 2017 | 303 | 0.350 |
Why?
| | Insecticide-Treated Bednets | 3 | 2021 | 6 | 0.350 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 540 | 0.350 |
Why?
| | Nerve Tissue Proteins | 4 | 2023 | 605 | 0.340 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2537 | 0.340 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 20 | 0.330 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 2135 | 0.330 |
Why?
| | Alzheimer Disease | 3 | 2015 | 595 | 0.330 |
Why?
| | Adenocarcinoma | 4 | 2017 | 896 | 0.330 |
Why?
| | Monocytes | 2 | 2025 | 579 | 0.330 |
Why?
| | Precision Medicine | 2 | 2025 | 434 | 0.330 |
Why?
| | Principal Component Analysis | 2 | 2023 | 198 | 0.320 |
Why?
| | Herpes Zoster | 2 | 2025 | 319 | 0.320 |
Why?
| | Models, Neurological | 2 | 2024 | 251 | 0.320 |
Why?
| | Child, Preschool | 9 | 2025 | 11512 | 0.320 |
Why?
| | Antioxidants | 1 | 2014 | 599 | 0.320 |
Why?
| | Gene Expression | 3 | 2014 | 1492 | 0.320 |
Why?
| | Colorado | 6 | 2025 | 4629 | 0.310 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 265 | 0.310 |
Why?
| | Stem Cells | 3 | 2020 | 603 | 0.310 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 111 | 0.310 |
Why?
| | Signal Transduction | 10 | 2025 | 5169 | 0.300 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 29 | 0.300 |
Why?
| | Gene Dosage | 1 | 2010 | 142 | 0.300 |
Why?
| | Risk Factors | 14 | 2025 | 10482 | 0.300 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 136 | 0.300 |
Why?
| | Aged | 29 | 2024 | 24746 | 0.290 |
Why?
| | Child | 16 | 2025 | 22414 | 0.290 |
Why?
| | Liver Neoplasms | 1 | 2015 | 741 | 0.290 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 294 | 0.290 |
Why?
| | Middle Aged | 34 | 2024 | 34647 | 0.290 |
Why?
| | Protein Array Analysis | 8 | 2009 | 56 | 0.290 |
Why?
| | Proteomics | 5 | 2009 | 1138 | 0.290 |
Why?
| | Carcinoma | 2 | 2007 | 230 | 0.290 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.280 |
Why?
| | Emigration and Immigration | 1 | 2008 | 56 | 0.280 |
Why?
| | Statistical Distributions | 1 | 2008 | 8 | 0.280 |
Why?
| | Probability | 3 | 2021 | 309 | 0.280 |
Why?
| | Chromosome Mapping | 6 | 2017 | 504 | 0.270 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1485 | 0.270 |
Why?
| | DNA Methylation | 4 | 2023 | 648 | 0.270 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 337 | 0.270 |
Why?
| | Research Design | 5 | 2021 | 1146 | 0.260 |
Why?
| | Flow Cytometry | 2 | 2022 | 1197 | 0.260 |
Why?
| | Tumor Burden | 1 | 2008 | 312 | 0.260 |
Why?
| | Proteome | 3 | 2007 | 485 | 0.250 |
Why?
| | Entropy | 2 | 2023 | 43 | 0.250 |
Why?
| | Pancreas | 2 | 2020 | 326 | 0.250 |
Why?
| | Adult | 27 | 2024 | 39391 | 0.250 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 256 | 0.240 |
Why?
| | Monte Carlo Method | 4 | 2017 | 150 | 0.240 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 200 | 0.240 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1077 | 0.230 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 28 | 0.230 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1401 | 0.230 |
Why?
| | Cell Proliferation | 5 | 2021 | 2506 | 0.230 |
Why?
| | False Positive Reactions | 4 | 2012 | 125 | 0.230 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 547 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 97 | 0.230 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 515 | 0.220 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2158 | 0.220 |
Why?
| | Cell Nucleus | 2 | 2019 | 609 | 0.220 |
Why?
| | Replication Origin | 1 | 2004 | 21 | 0.220 |
Why?
| | Herpesvirus 3, Human | 2 | 2025 | 336 | 0.220 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 171 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2023 | 2375 | 0.220 |
Why?
| | Fever | 2 | 2023 | 308 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3737 | 0.210 |
Why?
| | Viral Nonstructural Proteins | 1 | 2024 | 67 | 0.210 |
Why?
| | Dengue Virus | 1 | 2024 | 53 | 0.210 |
Why?
| | Weather | 1 | 2024 | 40 | 0.210 |
Why?
| | Data Curation | 1 | 2024 | 19 | 0.210 |
Why?
| | Leukemia | 1 | 2006 | 244 | 0.210 |
Why?
| | Adolescent | 12 | 2025 | 22130 | 0.210 |
Why?
| | Carrier Proteins | 2 | 2007 | 748 | 0.210 |
Why?
| | Ligands | 2 | 2016 | 667 | 0.210 |
Why?
| | Dengue | 1 | 2024 | 83 | 0.210 |
Why?
| | ROC Curve | 5 | 2020 | 590 | 0.210 |
Why?
| | Antigens | 1 | 2005 | 362 | 0.200 |
Why?
| | Histones | 4 | 2020 | 639 | 0.200 |
Why?
| | Cell Phone | 1 | 2024 | 82 | 0.200 |
Why?
| | Melanoma | 3 | 2005 | 792 | 0.200 |
Why?
| | Sample Size | 3 | 2008 | 128 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 1078 | 0.200 |
Why?
| | Coculture Techniques | 1 | 2004 | 245 | 0.200 |
Why?
| | Staining and Labeling | 1 | 2023 | 154 | 0.200 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 30 | 0.200 |
Why?
| | Skin Diseases, Parasitic | 1 | 2022 | 3 | 0.200 |
Why?
| | Recurrence | 5 | 2023 | 1111 | 0.200 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 156 | 0.200 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 498 | 0.190 |
Why?
| | Carcinogens | 1 | 2003 | 128 | 0.190 |
Why?
| | Organometallic Compounds | 1 | 2023 | 113 | 0.190 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 174 | 0.190 |
Why?
| | Personality | 1 | 2004 | 139 | 0.190 |
Why?
| | DNA, Complementary | 4 | 2007 | 274 | 0.190 |
Why?
| | Emphysema | 1 | 2023 | 116 | 0.190 |
Why?
| | Retina | 2 | 2016 | 314 | 0.190 |
Why?
| | Social Stigma | 1 | 2024 | 147 | 0.190 |
Why?
| | Biomedical Research | 2 | 2025 | 708 | 0.190 |
Why?
| | Breast Neoplasms | 7 | 2014 | 2257 | 0.190 |
Why?
| | Neuroimaging | 2 | 2015 | 281 | 0.190 |
Why?
| | Parasites | 1 | 2022 | 49 | 0.180 |
Why?
| | Estrogens | 2 | 2019 | 368 | 0.180 |
Why?
| | Construction Materials | 1 | 2021 | 17 | 0.180 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1243 | 0.180 |
Why?
| | Leishmania | 1 | 2021 | 3 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 502 | 0.180 |
Why?
| | Infant | 3 | 2024 | 9843 | 0.180 |
Why?
| | Zebrafish | 2 | 2016 | 504 | 0.180 |
Why?
| | Brain Waves | 1 | 2021 | 45 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2765 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 234 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 555 | 0.170 |
Why?
| | Analysis of Variance | 4 | 2024 | 1321 | 0.170 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 625 | 0.170 |
Why?
| | Young Adult | 11 | 2024 | 13749 | 0.170 |
Why?
| | Autoantibodies | 5 | 2020 | 1475 | 0.170 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 188 | 0.170 |
Why?
| | Mutation, Missense | 2 | 2016 | 340 | 0.170 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 57 | 0.170 |
Why?
| | Receptors, Androgen | 2 | 2021 | 153 | 0.170 |
Why?
| | Epilepsy | 2 | 2021 | 349 | 0.170 |
Why?
| | Genotype | 8 | 2019 | 1866 | 0.170 |
Why?
| | Anxiety Disorders | 1 | 2004 | 380 | 0.170 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 103 | 0.170 |
Why?
| | Amino Acid Motifs | 2 | 2019 | 225 | 0.170 |
Why?
| | Peptides | 4 | 2007 | 979 | 0.170 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 74 | 0.160 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 312 | 0.160 |
Why?
| | RNA, Messenger | 8 | 2024 | 2828 | 0.160 |
Why?
| | Lymphocytes | 2 | 2023 | 398 | 0.160 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 106 | 0.160 |
Why?
| | Mexican Americans | 3 | 2008 | 114 | 0.160 |
Why?
| | Radiography | 1 | 2022 | 844 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 189 | 0.160 |
Why?
| | Androgens | 3 | 2012 | 187 | 0.160 |
Why?
| | Exome | 2 | 2018 | 238 | 0.150 |
Why?
| | Phosphorylation | 3 | 2019 | 1774 | 0.150 |
Why?
| | Protein Binding | 5 | 2019 | 2242 | 0.150 |
Why?
| | Hospital Mortality | 1 | 2024 | 924 | 0.150 |
Why?
| | Tretinoin | 1 | 2020 | 122 | 0.150 |
Why?
| | Disease Reservoirs | 1 | 2019 | 25 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 568 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 881 | 0.150 |
Why?
| | Prognosis | 11 | 2021 | 4080 | 0.150 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 44 | 0.150 |
Why?
| | Mice | 16 | 2025 | 18109 | 0.150 |
Why?
| | Disease | 1 | 2019 | 102 | 0.150 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 60 | 0.150 |
Why?
| | Bone Regeneration | 1 | 2019 | 26 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 69 | 0.150 |
Why?
| | Molecular Sequence Data | 4 | 2015 | 2929 | 0.150 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2608 | 0.150 |
Why?
| | Artificial Intelligence | 3 | 2008 | 337 | 0.150 |
Why?
| | Radiology Information Systems | 1 | 2018 | 33 | 0.150 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 98 | 0.140 |
Why?
| | Pilot Projects | 2 | 2021 | 1826 | 0.140 |
Why?
| | Precancerous Conditions | 1 | 2020 | 166 | 0.140 |
Why?
| | Pituitary Gland | 2 | 2009 | 150 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 859 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 65 | 0.140 |
Why?
| | Genetic Markers | 3 | 2015 | 343 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 110 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 470 | 0.140 |
Why?
| | Nuclear Proteins | 2 | 2019 | 719 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2019 | 88 | 0.140 |
Why?
| | Intensive Care Units | 1 | 2024 | 871 | 0.140 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2024 | 106 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 124 | 0.140 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 890 | 0.140 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 40 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 79 | 0.140 |
Why?
| | CD24 Antigen | 1 | 2017 | 19 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 627 | 0.130 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 22 | 0.130 |
Why?
| | Pregnancy | 5 | 2019 | 7092 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 158 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 154 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 114 | 0.130 |
Why?
| | Osteogenesis | 1 | 2019 | 199 | 0.130 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 111 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5697 | 0.130 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 676 | 0.130 |
Why?
| | Beryllium | 1 | 2018 | 161 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 175 | 0.130 |
Why?
| | Antley-Bixler Syndrome Phenotype | 1 | 2016 | 1 | 0.130 |
Why?
| | Up-Regulation | 2 | 2018 | 860 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 80 | 0.130 |
Why?
| | Calcium Compounds | 1 | 2016 | 6 | 0.130 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 44 | 0.130 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 278 | 0.130 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1487 | 0.130 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 6 | 0.130 |
Why?
| | RNA, Viral | 2 | 2024 | 693 | 0.130 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 5 | 0.130 |
Why?
| | Normal Distribution | 2 | 2014 | 21 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 163 | 0.130 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 160 | 0.130 |
Why?
| | Memory, Short-Term | 1 | 2019 | 267 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 654 | 0.120 |
Why?
| | Mosquito Control | 1 | 2016 | 28 | 0.120 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 38 | 0.120 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 962 | 0.120 |
Why?
| | Transcription Factors | 6 | 2017 | 1712 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 502 | 0.120 |
Why?
| | Anus Neoplasms | 1 | 2016 | 35 | 0.120 |
Why?
| | ErbB Receptors | 2 | 2012 | 610 | 0.120 |
Why?
| | Oxides | 1 | 2016 | 50 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 467 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 406 | 0.120 |
Why?
| | Respiratory Sounds | 2 | 2007 | 109 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 378 | 0.120 |
Why?
| | Endopeptidases | 1 | 2016 | 86 | 0.120 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 32 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 584 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 910 | 0.120 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 30 | 0.120 |
Why?
| | X-Ray Diffraction | 1 | 2016 | 104 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 227 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 372 | 0.120 |
Why?
| | Berylliosis | 1 | 2018 | 193 | 0.120 |
Why?
| | Anal Canal | 1 | 2016 | 104 | 0.120 |
Why?
| | Heart Arrest | 1 | 2020 | 385 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 382 | 0.120 |
Why?
| | Cough | 2 | 2007 | 133 | 0.120 |
Why?
| | Aged, 80 and over | 13 | 2022 | 7923 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 334 | 0.120 |
Why?
| | Oleic Acid | 1 | 2015 | 42 | 0.120 |
Why?
| | Anesthesiologists | 1 | 2016 | 65 | 0.120 |
Why?
| | Proteolysis | 1 | 2016 | 175 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 306 | 0.120 |
Why?
| | Mutation | 2 | 2025 | 4015 | 0.120 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1374 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 384 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2021 | 571 | 0.120 |
Why?
| | Schizophrenia | 1 | 2019 | 454 | 0.110 |
Why?
| | Risk | 1 | 2017 | 907 | 0.110 |
Why?
| | HIV Infections | 3 | 2022 | 3022 | 0.110 |
Why?
| | Air Pollution | 2 | 2017 | 322 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 408 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2020 | 2006 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 408 | 0.110 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 805 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 302 | 0.110 |
Why?
| | Blood Glucose | 2 | 2022 | 2278 | 0.110 |
Why?
| | Discriminant Analysis | 3 | 2020 | 37 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 730 | 0.110 |
Why?
| | Time Factors | 5 | 2016 | 6966 | 0.110 |
Why?
| | Ants | 1 | 2014 | 27 | 0.110 |
Why?
| | Catalysis | 2 | 2012 | 320 | 0.110 |
Why?
| | Metmyoglobin | 1 | 2014 | 2 | 0.110 |
Why?
| | Executive Function | 1 | 2019 | 460 | 0.110 |
Why?
| | Sulfonic Acids | 1 | 2014 | 18 | 0.110 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 53 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 354 | 0.110 |
Why?
| | Survival Rate | 4 | 2019 | 1972 | 0.100 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 86 | 0.100 |
Why?
| | Influenza Vaccines | 1 | 2019 | 551 | 0.100 |
Why?
| | Antiprotozoal Agents | 1 | 2013 | 16 | 0.100 |
Why?
| | Chromatography, Gel | 1 | 2014 | 131 | 0.100 |
Why?
| | Benzothiazoles | 1 | 2014 | 41 | 0.100 |
Why?
| | Amphotericin B | 1 | 2013 | 36 | 0.100 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 87 | 0.100 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 3495 | 0.100 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2938 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 235 | 0.100 |
Why?
| | Brain Diseases | 1 | 2015 | 149 | 0.100 |
Why?
| | Vaccines, Synthetic | 2 | 2025 | 139 | 0.100 |
Why?
| | Odds Ratio | 3 | 2020 | 1057 | 0.100 |
Why?
| | Crystallization | 1 | 2014 | 146 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 129 | 0.100 |
Why?
| | Trans-Activators | 3 | 2020 | 394 | 0.100 |
Why?
| | Cohort Studies | 8 | 2017 | 5815 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 626 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2023 | 5212 | 0.100 |
Why?
| | Estradiol | 2 | 2014 | 528 | 0.100 |
Why?
| | Rhodium | 1 | 2012 | 2 | 0.090 |
Why?
| | Interleukin-2 | 2 | 2025 | 456 | 0.090 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 310 | 0.090 |
Why?
| | Androstadienes | 1 | 2012 | 78 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 9 | 0.090 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2022 | 38 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1275 | 0.090 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 78 | 0.090 |
Why?
| | Silver | 1 | 2012 | 38 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2025 | 918 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2007 | 430 | 0.090 |
Why?
| | Gene Silencing | 3 | 2007 | 197 | 0.090 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 27 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 907 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1178 | 0.090 |
Why?
| | Motion | 1 | 2012 | 101 | 0.090 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 13 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2020 | 1132 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2024 | 987 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 16 | 0.090 |
Why?
| | Heme | 1 | 2012 | 76 | 0.090 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.090 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 92 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2025 | 852 | 0.090 |
Why?
| | Caspase 2 | 1 | 2011 | 13 | 0.090 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 11 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 99 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 998 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2022 | 346 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 692 | 0.090 |
Why?
| | Catalytic Domain | 1 | 2012 | 224 | 0.090 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 234 | 0.090 |
Why?
| | Lipid Bilayers | 1 | 2012 | 106 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 168 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 3294 | 0.080 |
Why?
| | Chemokines | 1 | 2011 | 228 | 0.080 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 510 | 0.080 |
Why?
| | Lung | 2 | 2023 | 4137 | 0.080 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 861 | 0.080 |
Why?
| | Pediatrics | 1 | 2019 | 1100 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 151 | 0.080 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.080 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1130 | 0.080 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 92 | 0.080 |
Why?
| | Vaccination | 1 | 2019 | 1472 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1087 | 0.080 |
Why?
| | Rural Population | 1 | 2014 | 606 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
| | Prevalence | 2 | 2015 | 2799 | 0.080 |
Why?
| | Antibody Formation | 2 | 2007 | 298 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2003 | 427 | 0.080 |
Why?
| | Autoimmunity | 2 | 2025 | 908 | 0.080 |
Why?
| | Sarcosine | 1 | 2009 | 10 | 0.080 |
Why?
| | Decision Trees | 2 | 2020 | 82 | 0.080 |
Why?
| | CpG Islands | 2 | 2023 | 165 | 0.080 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 20 | 0.070 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 128 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2016 | 962 | 0.070 |
Why?
| | Peptide Library | 2 | 2007 | 95 | 0.070 |
Why?
| | Genes, Recessive | 1 | 2008 | 78 | 0.070 |
Why?
| | Acculturation | 1 | 2008 | 55 | 0.070 |
Why?
| | Homozygote | 1 | 2008 | 201 | 0.070 |
Why?
| | Psoriasis | 1 | 2009 | 111 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 16374 | 0.070 |
Why?
| | Complex Mixtures | 1 | 2007 | 12 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 656 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 33 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 860 | 0.070 |
Why?
| | Uncertainty | 1 | 2008 | 139 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 49 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2008 | 329 | 0.070 |
Why?
| | Models, Molecular | 2 | 2019 | 1604 | 0.070 |
Why?
| | Proteins | 2 | 2003 | 1015 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 691 | 0.070 |
Why?
| | Xenopus | 1 | 2007 | 89 | 0.070 |
Why?
| | Glaucoma | 1 | 2010 | 241 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 385 | 0.070 |
Why?
| | Leisure Activities | 1 | 2007 | 30 | 0.070 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 33 | 0.070 |
Why?
| | Genes, myc | 1 | 2007 | 48 | 0.070 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.070 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 326 | 0.070 |
Why?
| | Nails | 1 | 2007 | 13 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1344 | 0.060 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 197 | 0.060 |
Why?
| | Self Concept | 1 | 2009 | 262 | 0.060 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 120 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1317 | 0.060 |
Why?
| | Genome, Human | 4 | 2016 | 421 | 0.060 |
Why?
| | Exercise | 1 | 2018 | 2112 | 0.060 |
Why?
| | Nepal | 2 | 2016 | 31 | 0.060 |
Why?
| | Genome, Bacterial | 2 | 2006 | 150 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 75 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3789 | 0.060 |
Why?
| | Pharynx | 1 | 2006 | 61 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 127 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2006 | 339 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2006 | 41 | 0.060 |
Why?
| | Arsenic | 1 | 2007 | 63 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 63 | 0.060 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 579 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 30 | 0.060 |
Why?
| | Biotinylation | 1 | 2005 | 32 | 0.060 |
Why?
| | Apoptosis | 3 | 2021 | 2576 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 25 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 152 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 632 | 0.060 |
Why?
| | Molecular Mimicry | 1 | 2005 | 42 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 13 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 364 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2005 | 52 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 201 | 0.060 |
Why?
| | Hydrogen Bonding | 1 | 2005 | 168 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 57 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 55 | 0.060 |
Why?
| | United States | 7 | 2018 | 15310 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 103 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2005 | 391 | 0.060 |
Why?
| | Family Characteristics | 2 | 2016 | 192 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2025 | 101 | 0.060 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 59 | 0.060 |
Why?
| | Disease-Free Survival | 3 | 2017 | 718 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 369 | 0.060 |
Why?
| | Area Under Curve | 2 | 2020 | 324 | 0.060 |
Why?
| | Mobile Health Units | 1 | 2024 | 21 | 0.060 |
Why?
| | Environmental Pollutants | 1 | 2007 | 165 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 368 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 255 | 0.050 |
Why?
| | Poisson Distribution | 1 | 2004 | 77 | 0.050 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 18 | 0.050 |
Why?
| | Lipids | 1 | 2009 | 690 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 1056 | 0.050 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 21 | 0.050 |
Why?
| | Bed Occupancy | 1 | 2024 | 16 | 0.050 |
Why?
| | Sputum | 1 | 2006 | 313 | 0.050 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 59 | 0.050 |
Why?
| | Culture Techniques | 1 | 2004 | 74 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 1920 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 44 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 167 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 386 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 14 | 0.050 |
Why?
| | Pedigree | 2 | 2019 | 511 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 58 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2007 | 371 | 0.050 |
Why?
| | Otitis Media | 1 | 2006 | 171 | 0.050 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 68 | 0.050 |
Why?
| | Body Mass Index | 2 | 2016 | 2385 | 0.050 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 2 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 876 | 0.050 |
Why?
| | Genetics, Population | 1 | 2005 | 209 | 0.050 |
Why?
| | Personality Inventory | 1 | 2004 | 144 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2023 | 120 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1656 | 0.050 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 42 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 441 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2020 | 329 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 67 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 136 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 67 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 287 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 85 | 0.050 |
Why?
| | Down-Regulation | 1 | 2025 | 641 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1474 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1562 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 99 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 176 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 322 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 136 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 133 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 855 | 0.050 |
Why?
| | Breast | 1 | 2003 | 158 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 10 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 133 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 41 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 139 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 250 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 720 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2005 | 333 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 2264 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 394 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 471 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 131 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2025 | 505 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2008 | 1158 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 180 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 100 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5909 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 30 | 0.050 |
Why?
| | Yeasts | 1 | 2002 | 52 | 0.050 |
Why?
| | Evaluation Studies as Topic | 1 | 2002 | 175 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2025 | 296 | 0.050 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 41 | 0.050 |
Why?
| | Seasons | 1 | 2024 | 546 | 0.040 |
Why?
| | Epithelial Cells | 2 | 2008 | 1114 | 0.040 |
Why?
| | Antigens, Protozoan | 1 | 2021 | 28 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 415 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2064 | 0.040 |
Why?
| | Japan | 1 | 2021 | 133 | 0.040 |
Why?
| | Health Care Surveys | 2 | 2016 | 566 | 0.040 |
Why?
| | Citrullination | 1 | 2020 | 13 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 510 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 463 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 206 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 399 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 3 | 0.040 |
Why?
| | Milk, Human | 1 | 2022 | 169 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 41 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 58 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 26 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 900 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 35 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 269 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 574 | 0.040 |
Why?
| | Policy | 1 | 2021 | 149 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 558 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 38 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2007 | 66 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 280 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 236 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 310 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 89 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 518 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 139 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 13 | 0.040 |
Why?
| | Disease Vectors | 1 | 2019 | 16 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 22 | 0.040 |
Why?
| | Quality of Life | 2 | 2009 | 3014 | 0.040 |
Why?
| | Skin | 2 | 2017 | 765 | 0.040 |
Why?
| | Leprosy | 1 | 2019 | 25 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1316 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 353 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 98 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 720 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4421 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 792 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 221 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 444 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 524 | 0.040 |
Why?
| | Virulence | 2 | 2011 | 268 | 0.040 |
Why?
| | Malaria | 1 | 2019 | 66 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 859 | 0.030 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 663 | 0.030 |
Why?
| | Seizures | 1 | 2021 | 442 | 0.030 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.030 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 41 | 0.030 |
Why?
| | Autoantigens | 1 | 2020 | 426 | 0.030 |
Why?
| | Xenodiagnosis | 1 | 2017 | 2 | 0.030 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 240 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 519 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 304 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2017 | 32 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 175 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1482 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2020 | 3071 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 48 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 600 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 46 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 87 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 132 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 213 | 0.030 |
Why?
| | Fibroblasts | 1 | 2002 | 1021 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 17 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2016 | 71 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 16 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 16 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 137 | 0.030 |
Why?
| | Population Density | 1 | 2016 | 97 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 89 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 68 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 173 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 166 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 203 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 381 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 51 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 96 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 504 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 855 | 0.030 |
Why?
| | Tuberculosis | 1 | 2019 | 286 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 310 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 737 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 196 | 0.030 |
Why?
| | Family | 1 | 2019 | 680 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 166 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 313 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1228 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 68 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5637 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 990 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 137 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1093 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 213 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 857 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 23 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 330 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 349 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 95 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 662 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2013 | 27 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 412 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 230 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2013 | 44 | 0.030 |
Why?
| | North America | 1 | 2014 | 307 | 0.030 |
Why?
| | Demography | 1 | 2014 | 296 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 312 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 118 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 187 | 0.020 |
Why?
| | Species Specificity | 1 | 2014 | 583 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2887 | 0.020 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 91 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 417 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 825 | 0.020 |
Why?
| | Cytokines | 1 | 2020 | 2100 | 0.020 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 95 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2193 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 146 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 105 | 0.020 |
Why?
| | Methane | 1 | 2012 | 49 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 75 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 38 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 771 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 237 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 320 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 260 | 0.020 |
Why?
| | Prospective Studies | 3 | 2009 | 7777 | 0.020 |
Why?
| | Self Report | 1 | 2014 | 861 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 32 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 16 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1313 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 696 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1508 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 4 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 387 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2491 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1748 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 38 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 386 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 51 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 49 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 321 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 309 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 120 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 100 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2169 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 30 | 0.020 |
Why?
| | Genes | 1 | 2008 | 229 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 333 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 252 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 3 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1793 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 28 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 29 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 510 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 46 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 179 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 5 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 2 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 250 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 4 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 453 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 25 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 396 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 20 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 47 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 44 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 27 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 55 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1334 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 30 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 992 | 0.020 |
Why?
| | Television | 1 | 2007 | 72 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 31 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 257 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 91 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 228 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1115 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 140 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 110 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 189 | 0.020 |
Why?
| | Ear, Middle | 1 | 2006 | 84 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 86 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 913 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5974 | 0.020 |
Why?
| | Urban Health | 1 | 2006 | 95 | 0.020 |
Why?
| | Drug Design | 1 | 2007 | 168 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1250 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1363 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2009 | 528 | 0.010 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1406 | 0.010 |
Why?
| | Databases as Topic | 1 | 2005 | 69 | 0.010 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 62 | 0.010 |
Why?
| | Base Composition | 1 | 2005 | 79 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 50 | 0.010 |
Why?
| | DNA Probes | 1 | 2005 | 59 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 368 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 38 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 6 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 98 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 43 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 56 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 43 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 367 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 439 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 206 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 149 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 337 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 96 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 264 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 31 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 19 | 0.010 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 84 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 588 | 0.010 |
Why?
| | Internet | 1 | 2007 | 690 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 73 | 0.010 |
Why?
| | California | 1 | 2003 | 466 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 600 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 187 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 210 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 561 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 624 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1664 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 943 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 912 | 0.010 |
Why?
| | RNA | 1 | 2005 | 930 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2075 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1158 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1924 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|